Oragenics, Inc. (OGEN)
0.4109
+0.01
(+1.38%)
USD |
NYAM |
Oct 23, 16:00
0.4109
0.00 (0.00%)
After-Hours: 20:00
Oragenics Enterprise Value : -2.036M for Oct. 22, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 22, 2026 | -2.036M |
| October 21, 2026 | -2.002M |
| October 20, 2026 | -1.906M |
| October 19, 2026 | -1.960M |
| October 16, 2026 | -1.902M |
| October 15, 2026 | -1.897M |
| October 14, 2026 | -1.892M |
| October 13, 2026 | -1.848M |
| October 12, 2026 | -1.845M |
| October 09, 2026 | -1.807M |
| October 08, 2026 | -1.775M |
| October 07, 2026 | -1.609M |
| October 06, 2026 | -1.676M |
| October 05, 2026 | -1.671M |
| October 02, 2026 | -1.664M |
| October 01, 2026 | -1.698M |
| September 30, 2026 | -1.645M |
| September 29, 2026 | -1.698M |
| September 28, 2026 | -1.736M |
| September 25, 2026 | -1.663M |
| September 24, 2026 | -1.595M |
| September 23, 2026 | -1.671M |
| September 22, 2026 | -1.518M |
| September 21, 2026 | -1.522M |
| September 18, 2026 | -1.713M |
| Date | Value |
|---|---|
| September 17, 2026 | -1.522M |
| September 16, 2026 | -1.608M |
| September 15, 2026 | -1.664M |
| September 14, 2026 | -1.613M |
| September 11, 2026 | -1.708M |
| September 10, 2026 | -1.593M |
| September 09, 2026 | -1.540M |
| September 08, 2026 | -1.508M |
| September 04, 2026 | -1.563M |
| September 03, 2026 | -1.615M |
| September 02, 2026 | -1.581M |
| September 01, 2026 | -1.613M |
| August 31, 2026 | -1.564M |
| August 28, 2026 | -1.499M |
| August 27, 2026 | -1.464M |
| August 26, 2026 | -1.473M |
| August 25, 2026 | -1.518M |
| August 24, 2026 | -1.520M |
| August 21, 2026 | -1.495M |
| August 20, 2026 | -1.428M |
| August 19, 2026 | -1.472M |
| August 18, 2026 | -1.401M |
| August 17, 2026 | -1.450M |
| August 14, 2026 | -1.460M |
| August 13, 2026 | -1.472M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.613B |
| Alnylam Pharmaceuticals, Inc. | 30.07B |
| Anika Therapeutics, Inc. | 269.09M |
| Savara, Inc. | 789.89M |
| Vericel Corp. | 2.131B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.529M |
| Total Expenses (Quarterly) | 2.529M |
| EPS Diluted (Quarterly) | -0.571 |
| Earnings Yield | -871.9% |
| Normalized Earnings Yield | -871.94 |